- Raised $60k grant, Aug 2025
- Raised $8k grant, Apr 2023
About
Haim Pharma Group is an Israel-based virtual drug development company, advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company's lead focus is Amyotrophic Lateral Sclerosis (ALS), with a parallel program in Parkinson's disease (PD). Haim Pharma Group is dedicated to developing stable, pharmaceutical-grade psilocin treatments designed to address the unique challenges of neurodegenerative diseases, including ALS, Parkinson's Disease (PD), and Alzheimer's Disease (AD). They focus on creating condition-specific formulations to deliver science-driven, targeted care, aiming to unlock the therapeutic potential of psilocin. The company emphasizes enhanced stability, pharmaceutical dosing precision, and regulatory compliance in their product development. Haim Pharma Group's mission is to pioneer innovative treatments that offer hope and improved quality of life for patients through precision medicine and cutting-edge research.
Funding history · 2 rounds · $68K total
Q&A
- What is Haim Pharma Group's primary focus in drug development?
- Haim Pharma Group (HPG) is focused on advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases, with a lead focus on amyotrophic lateral sclerosis (ALS) and a parallel program in Parkinson’s disease (PD).
- What is the name of Haim Pharma Group's pioneering oral psilocin capsule?
- Haim Pharma Group is pioneering an oral enteric-coated psilocin capsule named Neurosilin, designed for stability and controlled release.
- When did Haim Pharma Group file a U.S. provisional patent for its novel approach?
- A U.S. provisional patent protecting Haim Pharma Group's novel approach to treating neurodegenerative diseases was filed in 2025.
- What is Haim Pharma Group's regulatory strategy regarding the FDA?
- Haim Pharma Group engaged with the FDA and submitted a briefing package in July 2025, outlining its development strategy and clinical roadmap.
- How many employees does Haim Pharma Group currently have?
- Haim Pharma Group has 1-10 employees.
- Who is the founder of Haim Pharma Group?
- Miriam O’reilly is the CEO and founder of Haim Pharma Group.
- What was Haim Pharma Group's most recent funding round?
- Haim Pharma Group received a Grant in September 2025, with the Israel Innovation Authority as the lead investor.
- What is the total amount of funding Haim Pharma Group has raised to date?
- Haim Pharma Group has raised a total of $68,000 USD.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | haimpharmagroup.com |
|---|---|
| linkedin.com/company/haim-pharma |
Identifiers & details
| Legal name | HAIM PHARMA GROUP LTD |
|---|---|
| Founded | 2022-4 |
| Employees (exact) | 1 |
Radar intelligence
Patents
| EPO | 10 |
|---|
Web history (Wayback)
| Domain | haimpharmagroup.com |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516598612 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-04-13 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | משאבים 29 הוד השרון |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-29 | דו~ח שנתי |